Cholesteryl ester transfer protein and hepatic lipase gene polymorphisms: Effects on hepatic mRNA levels, plasma lipids and carotid atherosclerosis

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 374-380

  Soyal, Selma M ^a   Sandhofer, Anton ^b   Hahne, Penelope ^a   Oberkofler, Hannes ^a   Felder, Thomas ^a   Iglseder, Bernhard ^a   Miller, Karl ^c   Krempler, Franz ^c   Patsch, Josef R ^b   Paulweber, Bernhard ^a   Patsch, Wolfgang ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Krankenhaus Hallein   (Austria)

Author keywords

Carotid atherosclerosis; CETP; LIPC; Lipids; Lipoproteins; SNP

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA;

ADULT; AGED; ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; DNA POLYMORPHISM; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIPID BLOOD LEVEL; LIVER; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; CAROTID ARTERY DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GENOTYPE; HUMANS; LIPASE; LIPIDS; LIPOPROTEINS, HDL; LIVER; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; RISK;

EID: 79958006812     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.052     Document Type: Article

References (32)

1. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
2. Genest J.J., McNamara J.R., Salem D.N., Schaefer E.J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991, 67:1185-1189.
3. Rader D.J. Illuminating HDL - is it still a viable therapeutic target?. N Engl J Med 2007, 357:2180-2183.
4. Patsch J.R., Prasad S., Gotto A.M., Patsch W. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987, 80:341-347.
5. Thompson A., Di A.E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299:2777-2788.
6. Isaacs A., Sayed-Tabatabaei F.A., Njajou O.T., Witteman J.C., van Duijn C.M. The -514C>T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 2004, 89:3858-3863.
7. Jansen H., Verhoeven A.J., Sijbrands E.J. Hepatic lipase: a pro- or anti-atherogenic protein?. J Lipid Res 2002, 43:1352-1362.
8. Klerkx A.H., El H.K., van der Steeg W.A., et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 2006 Apr, 26(4):706-715.
9. Esterbauer H., Schneitler C., Oberkofler H., et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001, 28:178-183.
10. Iglseder B., Oberkofler H., Felder T.K., et al. Associations of PPARGC1A haplotypes with plaque score but not with intima-media thickness of carotid arteries in middle-aged subjects. Stroke 2006, 37:2260-2265.
11. Guerra R., Wang J., Grundy S.M., Cohen J.C. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1997, 94:4532-4537.
12. Deeb S.S., Peng R. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000, 41:155-158.
13. Schadt E.E., Molony C., Chudin E., et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008, 6:e107.
14. Freeman D.J., Griffin B.A., Holmes A.P., et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994, 14:336-344.
15. Heilbronn L.K., Noakes M., Clifton P.M. Association between HDL-cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. Atherosclerosis 2002, 162:419-424.
16. Boekholdt S.M., Sacks F.M., Jukema J.W., et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005, 111:278-287.
17. van Acker B.A., Botma G.J., Zwinderman A.H., et al. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis 2008, 200:161-167.
18. Talmud P.J., Hawe E., Robertson K., et al. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet 2002, 66:111-124.
19. Isaacs A., Aulchenko Y.S., Hofman A., et al. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. J Clin Endocrinol Metab 2007, 92:2680-2687.
20. Manolio T.A., Boerwinkle E., O'Donnell C.J., Wilson A.F. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:1567-1577.
21. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
22. Adams M.R., Nakagomi A., Keech A., et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995, 92:2127-2134.
23. Hegele R.A., Al-Shali K.Z., House A.A., et al. Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. Stroke 2005, 36:2566-2570.
24. Eller P., Schgoer W., Mueller T., et al. Hepatic lipase polymorphism and increased risk of peripheral arterial disease. J Intern Med 2005, 258:344-348.
25. Anand S.S., Xie C., Pare G., et al. Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: the INTERHEART Genetics Study. Circ Cardiovasc Genet 2009, 2:16-25.
26. Borggreve S.E., Hillege H.L., Wolffenbuttel B.H., et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006, 91:3382-3388.
27. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010, 121:366-374.
28. Vasan R.S., Pencina M.J., Robins S.J., et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.
29. Tanigawa H., Billheimer J.T., Tohyama J., et al. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 2007, 116:1267-1273.
30. Schwartz C.C., VandenBroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004, 45:1594-1607.
31. Regieli J.J., Jukema J.W., Grobbee D.E., et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008, 29:2792-2799.
32. Marschang P., Sandhofer A., Ritsch A., et al. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006, 260:151-159.